专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2020095183A1 COMBINATION FOR TREATING CANCER 审中-公开
公开(公告)号：WO2020095183A1
公开(公告)日：2020-05-14
申请号：PCT/IB2019/059459
申请日：2019-11-04
申请人： PFIZER INC. , MERCK PATENT GMBH , NEKTAR THERAPEUTICS , ASTELLAS PHARMA INC.
发明人： BOSHOFF, Christoffel Hendrik , CESARI, Rossano , MASSACESI, Cristian , CHARYCH, Deborah
IPC分类号： A61K31/4166 , A61K39/00 , A61P35/00 , A61K45/06 , C07K16/28 , A61K38/08
摘要： Provided herein are methods and combinations for treating a subject having cancer by administering to the subject a PD-1/PD-L1 axis inhibitor, a CD-122-biased- cytokine agonist, and an anti-androgen or a pharmaceutically acceptable salt thereof.

2. 发明申请

WO2020095184A1 COMBINATIONS FOR TREATING CANCER 审中-公开
公开(公告)号：WO2020095184A1
公开(公告)日：2020-05-14
申请号：PCT/IB2019/059460
申请日：2019-11-04
申请人： PFIZER INC. , MERCK PATENT GMBH , NEKTAR THERAPEUTICS
发明人： BOSHOFF, Christoffel Hendrik , CESARI, Rossano , MASSACESI, Cristian , CHARYCH, Deborah
IPC分类号： A61K31/5025 , A61K38/08 , A61K39/00 , A61K45/06 , A61P35/00 , C07K16/28
摘要： Provided herein are methods and combinations for treating a subject having cancer by administering to the subject a PD-1/PD-L1 axis inhibitor, a CD-122-biased- cytokine agonist, and optionally a PARP inhibitor.

3. 发明公开

EP3876940A1 COMBINATIONS FOR TREATING CANCER 审中-公开
公开(公告)号：EP3876940A1
公开(公告)日：2021-09-15
申请号：EP19802279.0
申请日：2019-11-04
申请人： Pfizer Inc. , Merck Patent GmbH , Nektar Therapeutics
发明人： BOSHOFF, Christoffel Hendrik , CESARI, Rossano , MASSACESI, Cristian , CHARYCH, Deborah
IPC分类号： A61K31/5025 , A61K38/08 , A61K39/00 , A61K45/06 , A61P35/00 , C07K16/28

4. 发明公开

EP3876929A1 COMBINATION FOR TREATING CANCER 审中-公开
公开(公告)号：EP3876929A1
公开(公告)日：2021-09-15
申请号：EP19802278.2
申请日：2019-11-04
申请人： Pfizer Inc. , Merck Patent GmbH , Nektar Therapeutics , Astellas Pharma Inc.
发明人： BOSHOFF, Christoffel Hendrik , CESARI, Rossano , MASSACESI, Cristian , CHARYCH, Deborah
IPC分类号： A61K31/4166 , A61K39/00 , A61P35/00 , A61K45/06 , C07K16/28 , A61K38/08

5. 发明申请

WO2017062832A1 COMBINATION OF AN IL-2RBETA-SELECTIVE AGONIST AND A LONG-ACTING IL-15 AGONIST 审中-公开
标题翻译： IL-2RBETA选择性激素和长期IL-15激动剂的组合
公开(公告)号：WO2017062832A1
公开(公告)日：2017-04-13
申请号：PCT/US2016/056088
申请日：2016-10-07
申请人： NEKTAR THERAPEUTICS
发明人： CHARYCH, Deborah , KIRK, Peter
IPC分类号： A61K38/20 , A61P35/00
CPC分类号： A61K38/2013 , A61K38/2086 , A61K2300/00
摘要： In one or more embodiments of the invention, a method is provided, the method comprising the steps of administering to a cancer patient: (a) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and (b) an IL-15R-activating amount of a long- acting, IL-15 moiety. In one or more embodiments of the invention, a composition is provided, the composition comprising: an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a kit is provided, the kit comprising: an IL-2Rβ- activating amount of a long-acting, IL-2Rβ-selective agonist; an IL-15R-activating amount of a long-acting, IL-15 moiety; and instructions for use of the IL-2Rβ-selective agonist and the long-acting, IL-15 moiety.
摘要翻译：在本发明的一个或多个实施方案中，提供了一种方法，所述方法包括以下步骤：向癌症患者施用：（a）IL-2Rβ活化量的长效IL-2Rβ选择性激动剂; 和（b）IL-15R活化量的长效IL-15部分。在本发明的一个或多个实施方案中，提供组合物，所述组合物包含：IL-2Rβ活化量的长效IL-2Rβ选择性激动剂; 和IL-15R活化量的长效IL-15部分。在本发明的一个或多个实施方案中，提供试剂盒，所述试剂盒包含：IL-2Rβ活化量的长效IL-2Rβ选择性激动剂; IL-15R活化量的长效IL-15部分; 以及使用IL-2Rβ选择性激动剂和长效IL-15部分的说明书。

6. 发明公开

EP3359182A1 COMBINATION OF AN IL-2RBETA-SELECTIVE AGONIST AND A LONG-ACTING IL-15 AGONIST 有权转让
公开(公告)号：EP3359182A1
公开(公告)日：2018-08-15
申请号：EP16791713.7
申请日：2016-10-07
申请人： Nektar Therapeutics
发明人： CHARYCH, Deborah , KIRK, Peter
IPC分类号： A61K38/20 , A61P35/00
CPC分类号： A61K38/2086 , A61K38/2013 , A61K47/60 , A61P35/00 , A61K2300/00
摘要： In one or more embodiments of the invention, a method is provided, the method comprising the steps of administering to a cancer patient: (a) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and (b) an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a composition is provided, the composition comprising: an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a kit is provided, the kit comprising: an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; an IL-15R-activating amount of a long-acting, IL-15 moiety; and instructions for use of the IL-2Rβ-selective agonist and the long-acting, IL-15 moiety.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式